TLR2 variants and

Duygu Kirkik, Sevgi Demircioglu, Sevgi Kalkanli Taş

Abstract readMeta-AnalysisSystematic Review

In one paragraph

Synthesis in Upsala journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Duygu KirkikDepartment of Immunology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul, Turkiye.

Sevgi DemirciogluDepartment of Computer Engineering, Faculty of Engineering, Istanbul Arel University, Istanbul, Turkiye.

Sevgi Kalkanli TaşDepartment of Immunology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul, Turkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Although polymorphisms in the Toll-like receptor 2 (TLR2) gene have been proposed as host genetic factors influencing susceptibility to Materials and methods: A systematic search of PubMed, Scopus, and Web of Science (up to January 2025) identified eligible case-control studies examining the association between TLR2 polymorphisms and Results: Ten studies comprising 4,521 subjects were included. Pooled analyses under allelic, dominant, recessive, homozygous, and heterozygous models revealed no significant association between either rs3804099 or del -196 to -174 polymorphisms and infection risk. Substantial inter-study heterogeneity was observed, particularly for rs3804099, but sensitivity analyses confirmed the stability of pooled results. Conclusion: This meta-analysis refutes a consistent genetic association between TLR2 rs3804099 or del -196 to -174 polymorphisms and

Indexed as

Helicobacter InfectionsHelicobacter pyloriToll-Like Receptor 2Case-Control StudiesGenetic Predisposition to DiseaseHumansOdds RatioPolymorphism, Single NucleotideTLR2 protein, humanToll-Like Receptor 2del –196 to –174Helicobacter pylorimeta-analysisrandom-effects modelTLR2

Identifiers

PMID41503064

DOI10.48101/ujms.v130.13533

PMCPMC12771068

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.